Mogamulizumab Q4week Dosing

Brief Summary:

This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.



Kyowa Kirin, Inc.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its identifier: NCT04745234

Contact: Kyowa Kirin, Inc. 609-919-1100


Participating Locations:

University of Pittsburgh School of Medicine
Pittsburgh, PA, United States
Sue McCann, MSN, RN, DNC